FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO-22 | Impact of sleep disorders on anti-CGRP monoclonal antibodies treatment response in migraine: a cross-sectional study Costanza Sottani,1 Valerio Brunetti,1,2 Fabiana Cerulli,1 Claudia Garattini,4 Gianluca Avino,5 Paolo Calabresi,1,3 Catello Vollono1,4 | 1Università Cattolica del Sacro Cuore, Dipartimento di Neuroscienze, Rome; 2Stroke Unit, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 3UOC Neurologia, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 4UOC Neurofisiopatologia, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 5Unità di Neurologia, Ospedale Santo Stefano, Prato, Italy
180 -
PO-78 | No changes in blood pressure assessed with the 24-hour Holter monitoring in patients treated with anti-CGRP monoclonal antibodies: a prospective observational study (SAFHYPER) Flavia Lo Castro,1 Niccolò Bonini,2 Luigi Francesco Iannone,1,3 Alberto Boccalini,1 Daria Brovia,1 Luca Pani,1,3 Giuseppe Boriani,2,3 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Cardiology Division, AOU Policlinico di Modena, Modena, Italy; 3Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy
276 -
PO-52 | Long-term efficacy of CGRP mAbs: new insights and current evidence Oreste Marsico,1 Marta Lioi,2 Rosario Iannacchero,3 Michele Trimboli3 | 1Department of Neuroscience, “Giovanni Paolo II” Hospital, Lamezia Terme, Catanzaro, Italy; 2Department of Neurology, Magna Graecia University, Catanzaro, Italy; 3Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy
133 -
PO-70 | A nomogram for the prediction of response to anti-CGRP mAbs: the CGRP score Marina Romozzi,1 Ammar Lokhandwala,2 Catello Vollono,1 David García-Azorín,3 Giulia Vigani,4 Francesco De Cesaris,4 Claudia Altamura,5 Fabrizio Vernieri,5 Paolo Calabresi,1 Sonia Di Tella,6 Luigi Francesco Iannone7 1Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 2Drexel University, Philadelphia, PA, USA; 3Hospital Universitario del Río Hortega, Valladolid, Headache Unit, Department of Neurology, Valladolid, Spain; 4Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy; 5 Neurologia, Dipartimento di Medicina e Chirurgia, Università Campus Bio-Medico di Roma, Rome, Italy; 6Dipartimento di Psicologia, Università Cattolica del Sacro Cuore, Milan, Italy; 7Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
196 -
PO-86 | CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies prophylaxis Alessia Bellotti,1 Davide Chiasserini,2 Alfredo Megaro,2 Daniela Fruttini,3 Pierluigi Navarra,4 Giuseppe Tringali,4 Paolo Calabresi,5 Lucilla Parnetti,1 Paola Sarchielli1 | 1Department of Medicine and Surgery, Section of Neurology, University of Perugia, Perugia, Italy; 2Department of Medicine and Surgery, Section of Physiology and Biochemistry, University of Perugia, Perugia, Italy; 3Department of Medicine and Surgery, Section of Internal Medicine, University of Perugia, Perugia, Italy; 4Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Catholic University Medical School, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy; 5Department of Medicine and Surgery, Section of Neurology, Catholic University Medical School, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy
258 -
PO-39 | Leeds Dependence Questionnaire (LDQ) in migraine: diagnostic utility without predictive value for anti-CGRP (R) response Antonio Munafò,1 Andrea Burgalassi,1 Giulia Vigani,2 Francesco De Cesaris,1 Alberto Chiarugi1,2 | 1Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy; 2Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
219 -
PO-77 | Real-world evidence of Atogepant efficacy in patients unresponsive to anti-CGRP monoclonals Matteo Cortinovis, Marco Bolchini, Paola Zavarise, Giulia Campana, Giorgio Dalla Volta | Headache Center, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia, Italy
314 -
OC-13 | Monoclonal antibodies targeting CGRP differently affect sleep and psychiatric comorbidities in reproductive and postmenopausal chronic migraine women Giulia Procopio, Letizia Curto, Antonia Di Chirico, Leonardo Troilo, Gabriele Siciliano, Filippo Baldacci, Sara Gori | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
384 -
PO-41 | Eptinezumab for difficult-to-treat migraine: who responds and who needs more Alessandro Visentini,1,2,3 Roberta Messina,1,2,3 Ilaria Cetta,1,2,3 Edorardo Ratto,1 Laura Zanandrea,1,3 Federica Genovese,1,2,3 Irene Chinali,1 Bruno Colombo,1 Massimo Filippi1,2,3 | 1Neurology Unit and 2Neuroimaging Research Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; 3Vita-Salute San Raffaele University, Milan, Italy
238 -
PO-21 | Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: a retrospective optical coherence tomography study Chiara Serafini,1 Massimo Cesareo,2 Alessio Martucci,2 Marco Lombardo,2 Vittoria Carla D’Agostino,1 Alessandro Stefani,3 Carlo Nucci,2 Nicola Biagio Mercuri,1,3 Maria Albanese1,3 | 1Regional Referral Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome, Italy 2Ophthalmology Unit, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome; 3Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
232 -
OC-17 | Profiling miR-30a expression in patients with episodic and chronic migraine Elisa Rubino,1,2 Elisa Maria Piella,1 Giulia Cicilese,1,3 Silvia Boschi,1 Alberto Mario Chiarandon,1 Elena Tamagno,1,3 Michela Guglielmotto,1,3 Innocenzo Rainero1,2 | 1Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Turin, Italy; 2Headache Center, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino; 3Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano (TO), Italy
122 -
PO-43 | Eptinezumab in migraine patients unresponsive to prior subcutaneous CGRP(-R) monoclonal antibody treatment: a retrospective case series Elena Cresta, Irene Mattioli, Michele Di Pasquale, Alice Lanfranchi, Renata Rao, Alessandro Padovani | Neurology Unit and Headache Centre, Dipartimento di continuità di cura e fragilità, ASST Spedali Civili e Università degli studi di Brescia, Brescia, Italy
240 -
OC-05 | Mid-term effectiveness and tolerability of atogepant in the prevention of migraine: a real life, prospective, multicentric study (the STAR study) Fabrizio Vernieri,1 Luigi Francesco Iannone,2,3 Gabriele Sebastianelli,4 Flavia Lo Castro,2, Federico De Santis,5 Michele Corrado,6 Marilena Marcosano,1 Raffaele Ornello,5 Licia Grazzi,7 Danilo Antonio Montisano,7 Francesco De Cesaris,8 Antonio Munafò,8 Gianluca Avino,9 Michele Trimboli,10 Maria Albanese,11 Antonio Russo,12 Giorgio Dalla Volta,13 Marina Romozzi,14 Paola Merlo,15 Maria Pia Prudenzano,16 Maria Rosaria Valente,17 Innocenzo Rainero,18 Giada Giuliani,19 Luisa Fofi,1 Alberto Doretti,20 Gloria Vaghi,6 Francesca Pistoia,5 Delfina Ferrandi,21 Stefania Battistini,22 Simona Sacco,5 Simona Guerzoni,2 Claudia Altamura1 on behalf of the Italian Headache Registry (RICe) Study Group | 1Fondazione Policlinico Campus Bio-Medico, Roma; 2AOU Policlinico di Modena; 3Università di Modena e Reggio Emilia. 4Sapienza University of Rome Polo Pontino, Latina; 5University of L’Aquila; 6University of Pavia, Pavia, Italy and IRCCS Mondino Foundation, Pavia; 7IRCCS Istituto Neurologico Carlo Besta, Milano; 8AOU Careggi, Firenze; 9SOC Neurologia, Ospedale di Prato, Prato; 10Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 11Università Roma Tor Vergata, Roma; 12Università della Campania "Luigi Vanvitelli", Napoli; 13U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 14Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma; 15UO di Neurologia, Humanitas Gavazzeni, Bergamo; 16Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale di Bari; 17Dipartimento di Neuroscienze, Azienda Sanitaria Universitaria Integrata di Udine; 18Dipartimento di Neuroscienze, Città della Salute e della Scienza di Torino; 19Centro per la diagnosi e terapia delle cefalee, Policlinico Umberto I, Roma; 20IRCCS Istituto Auxologico Italiano, Milano; 21AOU Alessandria; 22University of Siena, Siena, Italy
251 -
PO-76 | Atogepant reduces psychological dependence to acute treatments evaluated with the Leeds dependence questionnaire (LDQ): a prospective observational study Luigi Francesco Iannone,1,2 Marina Romozzi,3,4 Alberto Boccalini,1 Flavia Lo Castro,1 Claudia Altamura,5 Fabrizio Vernieri,5 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
241 -
PO-69 | Three-month atogepant treatment modulates dopaminergic-related functional connectivity in episodic migraine Davide Fedeli,1 Danilo Antonio Montisano,1 Greta Demichelis,1 Giuseppe Ciullo,1,2 Jean Paul Medina Carrion,1 Maria Grazia Bruzzone,1 Emilio Ciusani,1 Alessandra Erbetta,1 Marina Grisoli,1 Erika Guastafierro,1 Domenico D’Amico,1 Alberto Raggi,1 Anna Nigri,1 Licia Grazzi1 | 1Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 2University of Parma, Parma, Italy
185 -
OC-09 | Atogepant in treatment-refractory chronic migraine: is a revision of current criteria for refractory migraine appropriate? Lorenzo Tartaglione, Marcello Silvestro, Ilaria Orologio, Marcella Marziani, Francesco Maurizio Chianese, Pasquale Sozio, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo | Headache Center, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy
323 -
PO-62 | Preventive migraine treatment in patients under 25: a 24-month observational study on adherence, therapeutic switching, and prescription determinant factors Marilena Marcosano,1 Nicoletta Brunelli,1 Luisa Fofi,1 Laura Papetti,2 Fabiana Ursitti,2 Massimiliano Valeriani,2 Fabrizio Vernieri,1 Claudia Altamura1 | 1Headache and Neurosonology Unit, Fondazione Policlinico Campus Biomedico di Rome, Rome, Italy; 2Developmental Neurology, Bambino Gesù Children Hospital, IRCCS, Rome, Italy
130 -
PO-80 | Real-world effectiveness of atogepant for the preventive treatment of migraine in a cohort of multi -refractory patients: a single center study M. De Luca,1 L. Ferraù,1 A. Cafarchio,2 M.S. Adragna,1 M. Autunno1 | 1Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Department of Medicine and Health Sciences “Vincenzo Tibero” DIMES, University of Molise, Campobasso, Italy
244 -
PO-57 | Early treatment with atogepant improves sleep quality without sleep-related adverse events: a prospective observational study Alberto Boccalini,1 Luigi Francesco Iannone,1,2* Flavia Lo Castro,1 Daria Brovia,1 Marina Romozzi,3,4 Fabrizio Vernieri,5,6 Claudia Altamura,5,6 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
184 -
PO-56 | The role of bilateral greater occipital nerve block in resistant chronic migraine with medication overuse Leonardo Troilo, Letizia Curto, Giulia Procopio, Antonia Di Chirico, Gabriele Siciliano, Sara Gori, Filippo Baldacci | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
152 -
PO-19 | Unraveling the spectrum of migraine resistant to treatments: searching for novel biological PHEnotypes and theRApeutic approaches (SPHERA project) M. Giraudo,1,2 R. De Icco,1,2 G. Vaghi,1,2 V. Grillo,1,2 F. Bighiani,1,2 M. Corrado,2 A. Antoniazzi,1,2 F. Cammarota,1,2 B. Agostini,1,2 A. Solfrizzi,1,2 M. Allena,2 E. Guaschino,2 N. Ghiotto,2 R. Greco,2 C. Demartini,2 A. Zanaboni,1,2 M. Francavilla,1,2 S. Facchetti,1,2 G. Sances,2 C. Tassorelli1,2 | 1Department of Brain and Behavioral Sciences, University of Pavia; 2Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy
223
1 - 29 of 29 items